For the treatment of intermediate-2 and high-risk myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia in patients not eligible for haematopoietic stem cell transplantation.

Azacitidine is an antineoplastic agent believed to exert its effects by multiple mechanisms, including cytotoxicity on abnormal haematopoietic cells in the bone marrow and hypomethylation of DNA.

The cytotoxic effects are thought to be as a result of DNA, RNA and protein synthesis inhibition as well as the activation of DNA damage pathways.

It is recommended that patients be treated for a minimum of six cycles and treatment should be continued as long as the patient continues to benefit or until disease progression. Each cycle consists of 28 days and patients should be monitored for haematologic response/toxicity and renal toxicities.

View Vidaza drug record

Further information: Celgene


Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases